Sadra Medical is a technology company.
Sadra Medical has raised $58.0M across 3 funding rounds.
Sadra Medical has raised $58.0M in total across 3 funding rounds.
Sadra Medical has raised $58.0M in total across 3 funding rounds.
Sadra Medical's investors include GE Ventures, Longitude Capital.
Sadra Medical was a medical technology company developing the Lotus Valve System, a fully repositionable transcatheter aortic valve replacement (TAVR) device designed for percutaneous delivery to treat patients with severe aortic stenosis.[1][2][3] It served interventional cardiologists and high-risk patients unsuitable for open-heart surgery, solving the problem of imprecise valve placement in minimally invasive procedures by enabling accurate positioning, repositioning, and retrieval before final deployment.[1][3][5] The company demonstrated early clinical momentum through European feasibility studies and a first-in-human trial of its retrievable valve technology, culminating in its acquisition by Boston Scientific in 2011 for an upfront $193 million (after prior investment) plus up to $193 million in milestones.[1][3][6]
Sadra Medical emerged in the mid-2000s amid rising demand for less-invasive cardiac treatments, with Boston Scientific as an early strategic investor since 2006.[3] The company focused on pioneering transcatheter alternatives to surgical aortic valve replacement, achieving pivotal early traction via successful European feasibility studies for the Lotus Valve System and the first-in-human implantation of a retrievable, repositionable TAVR device.[1][3][5] Leadership, including CEO Ken Martin, emphasized the technology's potential to simplify procedures; this progress led directly to Boston Scientific's full acquisition in January 2011.[1][3][6]
Sadra Medical stood out in the structural heart space through these key innovations:
Sadra rode the early wave of TAVR adoption, a transformative trend shifting aortic stenosis treatment from high-mortality open surgery to catheter-based interventions, fueled by aging populations and advances in stent and delivery tech.[1][3][4] Timing was ideal in the late 2000s, as feasibility studies and first-in-human successes validated the approach amid regulatory momentum (e.g., potential FDA/CE Mark paths).[1][3][5] Market forces like Boston Scientific's cardiology expertise amplified its impact, integrating Sadra's tech into a major portfolio to accelerate commercialization and influence the structural heart ecosystem toward more precise, retrievable devices.[3][6]
Post-acquisition, Sadra's Lotus technology advanced under Boston Scientific, with milestones tied to regulatory approvals and revenues through 2016, embedding it into mainstream TAVR competition.[1][3] Evolving trends like expanded TAVR indications for lower-risk patients and next-gen iterative designs (e.g., further miniaturization) shaped its legacy, influencing devices from Medtronic and Edwards Lifesciences. Sadra's pioneering repositionability set a benchmark for procedural safety, underscoring how targeted medtech innovations can redefine cardiac care through acquisition-driven scale.
Sadra Medical has raised $58.0M across 3 funding rounds. Most recently, it raised $30.0M Series C in May 2009.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2009 | $30.0M Series C | GE Ventures, Longitude Capital | |
| Oct 1, 2006 | $19.0M Series B | GE Ventures, Longitude Capital | |
| Jun 1, 2004 | $9.0M Series A | GE Ventures, Longitude Capital |